ALLO
What one share of Allogene Therapeutics holds
Biological Products, (No Diagnostic Substances)
We are a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. We are developing a pipeline of “off-the-shelf” T cell product candidates that are designed to target and kill cancer cells in patients or eliminate pathogenic autoreactive cells in patients with autoimmune disorders.
Allogene Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.02 |
|---|---|
| Profit | −$0.65 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$0.40 |
| Cash and investments | $0.11 |
| Book value | $1.26 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2018 | — | −$7.31 | $0.11 | −$1.65 | $0.00 | — |
| 2019 | — | −$1.83 | $0.50 | −$1.86 | $0.00 | $5.06 |
| 2020 | — | −$2.63 | $0.55 | −$1.50 | $0.00 | $7.21 |
| 2021 | — | −$1.34 | $0.16 | −$1.52 | $0.00 | $6.49 |
| 2022 | $0.00 | −$2.38 | $0.04 | −$1.58 | $0.00 | $4.62 |
| 2023 | $0.00 | −$2.09 | $0.01 | −$1.52 | $0.00 | $3.04 |
| 2024 | $0.00 | −$1.32 | $0.00 | −$1.03 | $0.00 | $1.99 |
| 2025 | $0.01 | −$0.87 | $0.00 | −$0.68 | $0.00 | $1.28 |